The FDA has approved Iheezo ophthalmic gel for ocular surface anesthesia, according to a joint press release from Harrow and Sintetica.
Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% is the first branded ocular anesthetic approved for the U.S. ophthalmic market in almost 14 years, according to the release. Its safety and efficacy were supported by three studies, the first two investigating Iheezo’s effects in healthy volunteers and the third in participants undergoing cataract surgery.
The third study was the first time a U.S. drug candidate was studied in a surgical model for